The changing paradigm of atopic dermatitis therapy

Sheila F. Friedlander, Eric L. Simpson, Alan D. Irvine, Lawrence F. Eichenfield

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The pathophysiology of atopic dermatitis (AD) is complex, and future treatment options will likely be incorporated in a multimodal approach to management. The new, directed therapies that have been developed will likely be used in conjunction with concomitant continuous or intermittent use of standard therapies; the goal is to optimize therapeutic outcomes while minimizing adverse impacts on safety and cost. Current data regarding disease course and expression throughout life suggest that treatment strategies also will need to be adjusted as a patient grows. Research also indicates that interventions begun in infancy-such as the use of emollients-may mitigate or prevent AD signs and symptoms in children at high risk for the disease.

Original languageEnglish (US)
Pages (from-to)97S-99S
JournalSeminars in cutaneous medicine and surgery
Volume35
DOIs
StatePublished - Jun 1 2016

Keywords

  • Atopic dermatitis
  • Petrolatum
  • Pimecrolimus
  • Tacrolimus
  • Topical calcineurin inhibitors
  • Topical immunomodulators

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint

Dive into the research topics of 'The changing paradigm of atopic dermatitis therapy'. Together they form a unique fingerprint.

Cite this